Balancing the clinical outcomes and economics associated with thromboembolic prophylaxis

Orthopedics

Volumn 19, Issue 8 SUPPL., 1996, Pages 19-23

  Carter, Charles A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DEXTRAN; DIHYDROERGOTAMINE; ENOXAPARIN; HEPARIN; WARFARIN;

ARTICLE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; HUMAN; JOINT PROSTHESIS; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; OUTPATIENT; PHARMACOECONOMICS; PRACTICE GUIDELINE; SELF MEDICATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

COST OF ILLNESS; FIBRINOLYTIC AGENTS; HEALTH CARE REFORM; HUMANS; THROMBOEMBOLISM;

EID: 0029742871     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Silver D. An overview of venous thromboembolism prophylaxis. Am J Surg. 1991; 61:537-540.
2. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992; 67:417-423.
3. Nielson HK. Pathophysiology of venous thromboembolism. Semin Thromb Hemost. 1991; 17(supp 3):S250-S253.
4. Husted SE. Principles of thromboprophylaxis in surgical patients. Semin Thromb Hemost. 1991; 17(supp3):S254-S258.
5. Carter CA. The role of the hospital pharmacist in thromboerabolic prophylaxis therapy P&T. 1994; 19:1065-1085.
6. National Institutes of Health Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986; 256:744-749.
7. Clagett GP, Anderson FA Jr, Heit J, Levine MM, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995; 108:3125-3345.
8. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg. 1980; 191:207-218.
9. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987; 257:203-208.
10. Bergqvist D, Matzych T, Jendteg S, et al. The cost-effectiveness of prevention of posoperative thromboembolism. Acta Chir Scand. 1990; 56(suppl):S36-S41.
11. Paiement GD, Wessinger SJ, Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg. 1991; 161:519-524.
12. Ament PW, Bertolino JG. Enoxaparin in the prevention of deep venous thrombosis. Am Fam Physician. 1994;50:1763-1768.
13. Hawkins DW. DVT prophylaxis following hip-replacement surgery: a focus on enoxaparin. Hosp Pharm Rep. September 20, 1993:13.
14. Bakst A. Pharmacoeconomics and the formulary decision making process. Hosp Form. 1995; 30:42-50.
15. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995; 155:757-764.
16. Spiro TE, Colwell CW, Trowbridge AA. A clinical trial comparing the efficacy and safety of enoxaparin, a low molecular weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement surgery. Blood. 1992; 80(supp 1):167a.
17. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med. 1991; 114:545-551.
18. Carter CA, Brookfield RB. Outpatient thromboembolic prophylaxis following orthopedic surgery: treatment guidelines and economic analysis. Managed Care Medicine. 1996 (in press).